Yahoo Finance

Estimated Discount To Fair Value: 36.7%

Vimian Group, trading at SEK37.9, is priced significantly below its estimated fair value of SEK59.88, highlighting potential undervaluation based on cash flows. The company reported strong fourth-quarter results with sales rising to €104.9 million from €82.5 million and net income reaching €12.2 million from a previous loss of €6.5 million, showcasing robust earnings growth prospects with forecasted annual profit increases of over 40%, despite a relatively modest revenue growth rate compared to the broader market expectations.

• Insights from our recent growth report point to a promising forecast for Vimian Group's business outlook.

• Get an in-depth perspective on Vimian Group's balance sheet by reading our health report here.

Xvivo Perfusion

Overview: Xvivo Perfusion AB (publ) is a medical technology company that develops and markets machines and perfusion solutions to optimize organ conditions for transplantation across various global regions, with a market cap of SEK13.12 billion.

Operations: The company's revenue is derived from three main segments: Services (SEK87.76 million), Thoracic (SEK555.24 million), and Abdominal (SEK179.42 million).

Estimated Discount To Fair Value: 13.2%

Xvivo Perfusion, trading at SEK416.5, is priced 13.2% below its estimated fair value of SEK479.89, suggesting undervaluation based on cash flows. The company reported substantial annual sales growth to SEK822.42 million from SEK597.54 million and net income increased to SEK172.18 million from SEK91.82 million year-over-year, despite a decline in quarterly net income compared to the previous year, with earnings expected to grow significantly over the next three years at 39.2% annually.

• Our comprehensive growth report raises the possibility that Xvivo Perfusion is poised for substantial financial growth.

• Click here and access our complete balance sheet health report to understand the dynamics of Xvivo Perfusion.

Taking Advantage

• Reveal the 204 hidden gems among our Undervalued European Stocks Based On Cash Flows screener with a single click here.

• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.

• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include HLSE:KALMAR OM:VIMIAN and OM:XVIVO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com